HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Market News Stocks News ETF News Crypto News

Sagimet Biosciences Inc.

Contributing Author

Recent Articles by Sagimet Biosciences Inc.

Dec-18
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination SGMT GlobeNewswire
Dec-17
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination Program SGMT GlobeNewswire
Dec-10
Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration SGMT GlobeNewswire
Dec-09
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SGMT GlobeNewswire
Nov-20
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference SGMT GlobeNewswire
Nov-13
Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates SGMT GlobeNewswire
Nov-10
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD-The Liver Meeting 2025 SGMT GlobeNewswire
Oct-24
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference SGMT GlobeNewswire
Oct-14
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences SGMT GlobeNewswire
Oct-07
Sagimet Biosciences Announces Upcoming Presentation at AASLD-The Liver Meeting 2025 SGMT GlobeNewswire
Oct-01
Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination SGMT GlobeNewswire
Sep-24
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week SGMT GlobeNewswire
Sep-17
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis SGMT GlobeNewswire
Sep-10
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit SGMT GlobeNewswire
Aug-26
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences SGMT GlobeNewswire
Aug-13
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates SGMT GlobeNewswire
Aug-05
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference SGMT GlobeNewswire
Jun-09
Sagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 2025 SGMT GlobeNewswire
Jun-04
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis SGMT GlobeNewswire
May-22
Sagimet Biosciences to Host Virtual KOL Event, "Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)" on May 29, 2025 SGMT GlobeNewswire
May-08
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates SGMT GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.